Indication

Pregabalin is an antiepileptic used as an adjunct in the treatment of partial seizures with or without secondary generalisation. It is also used in the treatment of generalised anxiety disorder and neuropathic pain.


Dosage & Administration

Pregabalin is given by mouth in 2 or 3 divided doses daily. Fibromyalgia: The initial dose is 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Postherpetic Neuralgia: Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 300 mg/day and who are able to tolerate Pregabalin, may be further increased to 300 mg two times a day (600 mg/day). Epilepsy: The initial adult dose is 150 mg daily increased after 1 week according to response to 300 mg daily and then to 600 mg daily after another week. Generalised Anxiety Disorder: The initial adult dose is 150 mg daily; this may be increased at weekly intervals in steps of 150 mg, to a maximum of 600 mg daily. Neuropathic Pain: The initial adult dose is 150 mg daily increased after 3 to 7 days according to response to 300 mg daily and then to 600 mg daily after another 7 days. Use in Children and Adolescents (<18 years of age): The safety and effectiveness of pregabalin has not been established in patients below the age of 18 years, with either epilepsy or neuropathic pain.

Administration in Renal Impairment

Creatinine

Clearance

(mL/min)

 

 

Total Pregabalin Daily dose *

 

Dose Regimen

 

 

 

 Starting dose (mg/day)

Max. dose (mg/day)  

> 60

 

150

600

 

BID or TID

 

 

 

 

 

 

30-60

 

75

300

 

BID or TID

 

 

 

 

 

 

15-30

 

25-50

150

 

QD or BID

< 15

 

25

75

 

QD

 

 

 

 

 

 

Supplementary dosage following haemodialysis (mg)

 

 

 

 

 

 

 

 

25

100

 

Single dose+

 

 

TID= Three divided doses; BID = Two divided doses; QD = Single daily dose
* Total daily dose (mg/day) should be divided as indicated by dose regimen to
provide mg/dose
+ Supplementary dose is a single additional dose


Precautions

Dizziness, somnolence, and blurred vision may impair a patient's ability to perform skilled tasks such as driving. Licensed drug information states that care is required when withdrawing pregabalin therapy, regardless of the indication. Use in pregnancy: Pregabalin has not been studied in pregnant women and Pregabalin should not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the fetus. Use in lactation: It is not known if pregabalin is excreted in the breast milk of humans; however, it is present in the milk of rats. Therefore, breastfeeding is not recommended in women taking Pregabalin.


Product Details


Related Products

Anzet

Flupentixol & Melitracen
Central Nervous Systems

Fosfen

Fosphenytoin Sodium
Central Nervous Systems

Clonapin

Clonazepam
Central Nervous Systems

Citalon

Escitalopram
Central Nervous Systems